NETWise Episode 4: Nuclear Medicine for NETs: PRRT- (See Episode 28 for the Updated Version)

This episode of NETRF’s NETWise podcast discusses Peptide Receptor Radionuclide Therapy (PRRT) a targeted form of radiotherapy approved in the U.S. in 2018. Listen in to hear others explain what it is, how it works, and who is most likely to benefit from PRRT. This therapy relies on a tumor’s expression of somatostatin receptors. We explain what they are and how to know if you have them.Then, we’ll take an objective look at the success rates for this therapy. What does research, like the NETTER-1 study, tell us about outcomes for this form of treatment? To give you information about both the pros and cons of PRRT, we will also discuss the potential side effects, from mild to serious. To give you a sense of what it is like to undergo PRRT, we’ll talk with multiple patients about their experience with the procedure itself, as well as the radiation safety precautions patients should take immediately following treatment. Finally, we look to the future asking about some of the new therapeutic directions PRRT is taking.

To download a copy of the transcript for this episode:
https://netrf.org/podcast/episode-4-n...

Link to the updated episode:
https://netrf.org/podcast/netwise-epi...

To listen to other NETWise episodes:
https://netrf.org/podcast/

NETWise is a podcast featuring neuroendocrine cancer experts and patients, produced by the Neuroendocrine Tumor Research Foundation (NETRF) in Boston, MA, USA.